MedTrace Logo

Lymphedema Screening

NCT04606511 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-02-24

No results posted yet for this study

Summary

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Currently, there is no established screening program for lymphedema. This cross-sectional study will investigate diagnostic modalities in screening for lymphedema in patients with and without known lymphedema after breast cancer.

Conditions

  • Lymphedema

Interventions

DIAGNOSTIC_TEST

Circumference tape measurements

centimeter and volume criterias

DIAGNOSTIC_TEST

Indocyanine green lymphangiography

Presence of dermal backflow

DIAGNOSTIC_TEST

bioimpedance spectroscopy

7.5 and 10 L-DEX criterias

DIAGNOSTIC_TEST

Symptom score

using lymph-icf, DASH and SF-36 questionnaires

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606511 on ClinicalTrials.gov